David Noyes

1.9k total citations
40 papers, 1.1k citations indexed

About

David Noyes is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Noyes has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 22 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Noyes's work include Cancer Immunotherapy and Biomarkers (17 papers), Immunotherapy and Immune Responses (16 papers) and CAR-T cell therapy research (9 papers). David Noyes is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Immunotherapy and Immune Responses (16 papers) and CAR-T cell therapy research (9 papers). David Noyes collaborates with scholars based in United States, Puerto Rico and Canada. David Noyes's co-authors include Scott Antonia, Melanie Mediavilla-Varela, Kingsley A. Boateng, Hatem Soliman, Carl A. Luer, Alberto Chiappori, Eric B. Haura, Anthony Neuger, Cathy J. Walsh and Brian Ruffell and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David Noyes

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Noyes United States	16	608	518	382	159	116	40	1.1k
Cláudia Silva Portugal	14	219 0.4×	259 0.5×	386 1.0×	26 0.2×	12 0.1×	41	1.1k
Yanan Sun China	20	135 0.2×	89 0.2×	579 1.5×	124 0.8×	26 0.2×	59	1.1k
Ying Tong China	19	216 0.4×	160 0.3×	392 1.0×	161 1.0×	15 0.1×	55	945
Pinar Uysal‐Onganer United Kingdom	22	176 0.3×	170 0.3×	912 2.4×	154 1.0×	11 0.1×	56	1.3k
Elizabeth T. Bartom United States	25	218 0.4×	300 0.6×	1.4k 3.8×	112 0.7×	10 0.1×	70	2.1k
Véronique Machelon France	11	364 0.6×	352 0.7×	256 0.7×	33 0.2×	11 0.1×	16	816
Masaki Yoda Japan	20	191 0.3×	153 0.3×	516 1.4×	48 0.3×	5 0.0×	44	1.0k
Heribert Appelhans Germany	16	112 0.2×	108 0.2×	475 1.2×	85 0.5×	39 0.3×	22	941
Daechan Park South Korea	17	152 0.3×	246 0.5×	602 1.6×	118 0.7×	3 0.0×	33	979
Linjie Tian China	17	162 0.3×	484 0.9×	247 0.6×	38 0.2×	15 0.1×	42	927

Countries citing papers authored by David Noyes

Since Specialization

Citations

This map shows the geographic impact of David Noyes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Noyes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Noyes more than expected).

Fields of papers citing papers by David Noyes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Noyes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Noyes. The network helps show where David Noyes may publish in the future.

Co-authorship network of co-authors of David Noyes

This figure shows the co-authorship network connecting the top 25 collaborators of David Noyes. A scholar is included among the top collaborators of David Noyes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Noyes. David Noyes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meads, Mark B., Xiaohong Zhao, David Noyes, et al.. (2024). De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression. Blood. 144(Supplement 1). 1906–1906.

Chen, Zhihua, Jiannong Li, Eslam Mohamed, et al.. (2021). Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunology Research. 9(5). 554–567. 19 indexed citations

Noyes, David, Melissa Alsina, Kenneth H. Shain, et al.. (2021). Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab. Blood. 138(Supplement 1). 2682–2682. 1 indexed citations

Puri, Sonam, et al.. (2019). P2.01-06 Phase I Study of Nivolumab and Ipilimumab Combined with Nintedanib in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S640–S641. 2 indexed citations

Creelan, Ben, Jamie K. Teer, Eric M. Toloza, et al.. (2018). OA05.03 Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC. Journal of Thoracic Oncology. 13(10). S330–S331. 6 indexed citations

Boyle, Theresa A., David Noyes, Kujtim Latifi, et al.. (2018). Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis. Journal of Thoracic Disease. 10(11). 6254–6260. 6 indexed citations

Gray, Jhanelle E., Alberto Chiappori, Tawee Tanvetyanon, et al.. (2018). A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunology Immunotherapy. 67(12). 1853–1862. 29 indexed citations

Mediavilla-Varela, Melanie, Alberto Chiappori, David Noyes, et al.. (2017). A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia. 19(7). 530–536. 72 indexed citations

Zheng, Hong, Weipeng Zhao, Cihui Yan, et al.. (2016). HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research. 22(16). 4119–4132. 264 indexed citations

10.

Mediavilla-Varela, Melanie, Kingsley A. Boateng, David Noyes, & Scott Antonia. (2016). The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer. 16(1). 176–176. 99 indexed citations

11.

Gray, Jhanelle E., Alberto Chiappori, Charles C. Williams, et al.. (2016). Phase I/II randomized trial of GM.CD40L vaccine plus/minus CCL21 in advanced lung adenocarcinoma: Final results.. Journal of Clinical Oncology. 34(15_suppl). 9037–9037. 3 indexed citations

12.

Mediavilla-Varela, Melanie, Kimberly A. Luddy, David Noyes, et al.. (2013). Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biology & Therapy. 14(9). 860–868. 81 indexed citations

13.

Creelan, Ben, Scott Antonia, David Noyes, et al.. (2013). Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell–based Vaccine for Refractory Lung Adenocarcinoma. Journal of Immunotherapy. 36(8). 442–450. 28 indexed citations

14.

Finkelstein, Steven E., Cristina Iclozan, Marilyn M. Bui, et al.. (2011). Combination of External Beam Radiotherapy (EBRT) With Intratumoral Injection of Dendritic Cells as Neo-Adjuvant Treatment of High-Risk Soft Tissue Sarcoma Patients. International Journal of Radiation Oncology*Biology*Physics. 82(2). 924–932. 101 indexed citations

15.

Fishman, Mayer, Terri Hunter, Hatem Soliman, et al.. (2008). Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma. Journal of Immunotherapy. 31(1). 72–80. 52 indexed citations

16.

Dessureault, Sophie, David Noyes, David Lee, et al.. (2006). A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease. Annals of Surgical Oncology. 14(2). 869–884. 35 indexed citations

17.

Walsh, Catherine J., A.B. Bodine, Clayton A. Smith, et al.. (2006). Elasmobranch immune cells as a source of novel tumor cell inhibitors: Implications for public health. Integrative and Comparative Biology. 46(6). 1072–1081. 17 indexed citations

18.

Walsh, Cathy J., et al.. (2005). Nitric oxide production by nurse shark (Ginglymostoma cirratum) and clearnose skate (Raja eglanteria) peripheral blood leucocytes. Fish & Shellfish Immunology. 20(1). 40–46. 13 indexed citations

19.

Dessureault, Sophie, Marwan Alsarraj, Susan McCarthy, et al.. (2005). A GM-CSF/CD40L Producing Cell Augments Anti-tumor T Cell Responses. Journal of Surgical Research. 125(2). 173–181. 16 indexed citations

20.

Walsh, Cathy J., Carl A. Luer, & David Noyes. (2004). Effects of environmental stressors on lymphocyte proliferation in Florida manatees, Trichechus manatus latirostris. Veterinary Immunology and Immunopathology. 103(3-4). 247–256. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact